CALT News and Press, Calliditas Therapeutics AB From 11/15/22

Calliditas Therapeutics ( OTCPK:CLTEF ) ( NASDAQ: CALT ) said China's National Medical Products Administration (NMPA) accepted to review Everest Medicines' new drug application (NDA) for kidney disease drug Nefecon. Calliditas said that Nefecon, if approved, w...

Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA PR Newswire STOCKHOLM , Nov. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today...

Calliditas Therapeutics press release ( NASDAQ: CALT ): Q3 GAAP EPS of SEK 0.21. Revenue of SEK 260.1M (+31.2% Y/Y). Cash amounted to SEK 736.2M and SEK 1,163.8M as of September 30, 2022 and 2021, respectively. "We expect to achieve net sales fr...

Calliditas Therapeutics: Interim Report Q3, 2022 PR Newswire Conditional Marketing Authorization in EU Granted for Kinpeygo ® STOCKHOLM , Nov. 14, 2022 /PRNewswire/ -- "On July 15th the European Commission issued the conditional ...

Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape PR Newswire STOCKHOLM , Nov. 7, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Le...

Calliditas Therapeutics' nomination committee composition for the AGM 2023 PR Newswire Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2023. STOCKHOLM , Oct. 21, 2022 /PRNewswire/ -- The nominatio...

Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy PR Newswire STOCKHOLM , Oct. 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("C...

Summary The key catalyst for Travere in the near term is the PDUFA date for sparsentan for the treatment of IgA nephropathy in early November. With a positive outcome anticipated, there might not be enough reward to hold the stock into the event. Given the recent slow launches...

Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy PR Newswire STOCKHOLM , Sept. 20, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") toda...

Summary Shares have risen by 50% since coming public via reverse merger in 2020. Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo. Competition in IgAN should not be underestimated from the likes of Travere Therapeutics, ...